Report: FDA Commissioner Scott Gottlieb Resigning
The Washington Post is reporting that FDA Commissioner Scott Gottlieb, M.D. is resigning. Gottlieb had only been in office since May 2017 but has been pushing a number of initiatives across the industries in which the FDA regulates. In November Gottlieb and CDRH Director Jeff Shuren, M.D., released the agency’s action plan to further improve device and patient safety. And in June 2018 he announced an innovation challenge to fight opioid misuse and abuse.
According to the Post article, Gottlieb wants to spend more time with his family, as he has been commuting between Washington and his home in Connecticut on a weekly basis. The article also reports that President Trump did not want Gottlieb to leave his post.
Related Articles
-
Califf faced strong opposition but was confirmed in a very close vote.
-
Effective February 7, the agency will conduct inspections across all commodities, as well as mission-critical foreign and domestic inspections.
-
The draft guidance proposes updates to clarify how the Breakthrough Devices Program may be applicable to certain medical devices that promote health equity, as well as considerations in designating eligible devices that may benefit populations impacted by disparities in health…
-
As of June 1, 2022, the Center for Devices and Radiological Health plans to accept all non-COVID in vitro diagnostic (IVD) pre-submissions.
About The Author
MedTech Intelligence Staff
The MedTech Intelligence staff consists of freelance journalists and industry contributing writers with decades of experience in covering medical device issues under the categories of business, market trends, product development, quality, regulatory, and operations.
You can contact our writing staff via our Contact Page.